Effect of Omalizumab (Xolair) in Treatment of Patients With AERD and Allergy Asthma
Status:
Unknown status
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
Double blind protocol treatment of 2/3 of the patients with omalizumab and 1/3 placebo
administer for 4 months. Patients selected for the study must have both aspirin exacerbated
respiratory disease and allergic asthma and rhinitis. They must also have completed aspirin
desensitization and be taking aspirin on a daily basis for the treatment of AERD.